0001193125-26-213399
SEC filingALX Oncology reduced its net loss to $17.9 million in Q1 2026, driven by lower operating expenses, while maintaining a cash runway through the first half of 2028.
ALX Oncology's operating loss for the first quarter of 2026 was $19.0 million, a 40.4% improvement from $31.8 million in the same period last year. This reduction reflects the company's strategic reprioritization of its pipeline and workforce reductions implemented in prior quarters. Research and development expenses decreased significantly as the company focused resources on its lead candidate evorpacept and early-stage ADC ALX2004, while discontinuing other programs. General and administrative expenses also declined due to lower personnel costs. The net loss of $17.9 million improved 41.7% from $30.8 million in Q1 2025, and diluted earnings per share improved to $(0.17) from $(0.58).
As of March 31, 2026, the company believes its existing cash, cash equivalents, and investments will fund operations through the first half of 2028. This runway provides a multi-year buffer to advance evorpacept through key clinical milestones. However, management expects to incur additional losses as it continues research and development and pre-commercialization activities, and acknowledges that additional capital will be required to fully implement its business plan. The company has historically funded operations through equity offerings and may seek further financing.
Evorpacept, a CD47-blocking agent with an inactive Fc domain, is designed for combination with other anti-cancer agents that provide a positive immune-stimulating signal. The company is advancing evorpacept in multiple clinical trials, including the single-arm ASPEN-09-Breast study. Key risks include clinical trial execution and potential FDA scrutiny under evolving accelerated approval guidance. The company also faces ongoing patent challenges from third-party SIRPα patents in Europe, though it believes it does not infringe the relevant U.S. patent.
Management expects to continue incurring losses as it advances evorpacept and ALX2004 through clinical development. The company acknowledges it will need to raise additional capital to fully implement its business plan, though the current cash runway provides a multi-year buffer. Key risks include clinical trial execution, particularly the single-arm ASPEN-09-Breast study which may face FDA scrutiny under evolving accelerated approval guidance, and the potential for further pipeline prioritization if data disappoint. The company also faces ongoing patent challenges from third-party SIRPα patents in Europe, though it believes it does not infringe the relevant U.S. patent.